Q-omics provides the consensus-scored FAM122B profile across patient tissues and cancer cell-line models. FAM122B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FAM122B is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, FAM122B RNA expression shows 19,739 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where FAM122B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM122B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM122B survival associations across molecular data types. FAM122B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM122B RNA expression–survival associations across cancer types. High FAM122B expression shows unfavorable associations in KIRP, LGG, COAD, HNSC and UCEC, but favorable associations in BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRP as the clearest survival context for FAM122B RNA expression.
This table summarizes FAM122B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for FAM122B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM122B shows higher tumor expression in HNSC, COAD, BLCA, LIHC, STAD and LUAD. The HNSC box plot shows higher FAM122B RNA expression in tumor versus normal tissue (log2 FC = +1.351, t-test p < 0.001).
This table shows molecular features associated with FAM122B in patient tissues and cancer cell lines. In patient samples, FAM122B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM122B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
